Abstract | BACKGROUND: METHODS: Our hospital's electronic pathology database was searched for cases with documentation of ' alemtuzumab' or 'anti-CD52' in the clinical history provided by either the ordering physician or the pathologist. Clinical and histopathologic review of the cases was performed. RESULTS: CONCLUSIONS: We describe the clinicopathologic features of a novel hypersensitivity reaction to alemtuzumb, and hypothesize it may be due to an immunologic response precipitated by the persistence of resident memory T-cells (TRM ) in the skin. Our findings raise awareness for a novel reaction pattern and guide the histopathologic interpretation of lesions which may clinically mimic residual or recurrent cutaneous lymphoproliferative disorders.
|
Authors | Stacie L Clark, Julie Y Tse, David C Fisher, Nicole R LeBeouf, George F Murphy, Thomas S Kupper, Rachael A Clark, Christine G Lian |
Journal | Journal of cutaneous pathology
(J Cutan Pathol)
Vol. 43
Issue 11
Pg. 989-993
(Nov 2016)
ISSN: 1600-0560 [Electronic] United States |
PMID | 27531597
(Publication Type: Journal Article)
|
Copyright | © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Alemtuzumab
|
Topics |
- Aged
- Aged, 80 and over
- Alemtuzumab
- Antibodies, Monoclonal, Humanized
(administration & dosage, immunology)
- Dermatitis
(etiology, pathology)
- Drug Hypersensitivity
(pathology)
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy)
- Lymphoma, T-Cell, Cutaneous
(drug therapy)
- Male
|